 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for March 18, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| TAK | Hot Stocks12:56 EDT Takeda kinase 2 inhibitor meets Phase 2 endpoints in psoriasis patients - Takeda announced "positive results" from a Phase 2b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index 75, 90 and 100 in the 5mg, 15mg and 30mg dosing arms compared to placebo at 12 weeks, the company said in a statement. In the Phase 2b study, 259 patients were randomized to receive one of four doses of TAK-279 once-daily, or placebo for 12 weeks.1 Results showed: A significantly greater proportion of TAK-279 patients achieved PASI 75 (44%, 68%, 67%; 5mg, 15mg, 30mg, respectively) versus placebo, meeting the study's primary endpoint. The frequency of adverse events was 53%-62% in the treatment arms and 44% in the placebo arm. Based on these Phase 2b results, Takeda will initiate a Phase 3 study of TAK-279 in psoriasis in fiscal 2023. Takeda expects topline results from a Phase 2b study in psoriatic arthritis in 2023 and will be evaluating TAK-279 in additional immune-mediated diseases including systemic lupus erythematosus and inflammatory bowel disease.
|
| SNY | Hot Stocks11:16 EDT Sanofi says moderate-to-severe atopic hand, foot dermatitis trial met endpoints - Sanofi reported "positive" results from the clinical trial assessing Dupixent in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today. The trial, which the company said is "the first evaluating a biologic for this difficult-to-treat population," met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology, or AAD, 2023 Annual Meeting. At 16 weeks, patients treated with Dupixent experienced the following: 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo, the primary endpoint; 52% saw a clinically meaningful reduction in itch on hands and feet compared to 14% with placebo, the key secondary endpoint; 69% average reduction in signs of hand and foot lesions from baseline compared to 31% with placebo; 75% average improvement in hand eczema disease severity from baseline compared to 40% with placebo. There were significant improvements in measures of hand and foot skin pain, sleep and hand eczema-related quality of life.
|
